The two groups were compared for clinical and virological parameters, namely AST, ALT, platelet count, HBV DNA titers, anti-HBe, relapse after NA withdrawal, antiviral treatment strategies, liver cirrhosis, HBV genotype, and HBV viral core promoter/precore mutations (see Table 1 for results). This evidence concerns the gene HBE1 and cirrhosis of liver.